Anti-RBD-3 antibody (EY6A)

General information on Anti-RBD-3 antibody

Anti-CoV-RBD Antibody is a fully human IgG immunoglobulin designed to target the receptor binding domain (RBD) of the novel pandemic SARS-CoV-2 coronavirus. When developing therapeutic antibodies for COVID-19, targeting this specific area has unique advantages. RBD is responsible for the recognition and binding of the specific cell surface marker ACE2 (Angiotensin Converting Enzyme 2). This interaction further leads to proteolytic tip cleavage, which exposes the S2 subunit and initiates the formation of the central membrane composite complex. Antibodies that can block this initial interaction are called neutralizing antibodies (NAbs). These specific and rare antibodies are at the forefront of COVID-19 treatment because they can prevent infection with SARS-CoV-2 at the earliest stage.
This novel antibody was obtained using phage display technology (i.e., biological scanning) to screen a diverse library of human COVID-19 antibodies (LiAb-SFCOVID-19 *) and express by RBD recombination as the desired target. It takes advantage of the immune pool generated in patients infected with COVID-19. In addition, the specificity and affinity of the newly developed molecules were tested on the ELISA platform. Stability and ease of production are further confirmed by consistently obtaining high yields in XtenCHO ™, which is a transient mammalian system based on the CHO variant.
In addition, by indirect detection and analysis: SARS-CoV-2 replaced the viral neutralization kit, the neutralizing activity of the R3P2-A2 antibody was confirmed in vitro. This analysis is based on the principle that the candidate antibody and ACE2 directly compete in the obligatory pocket of RBD. This antibody and other similar products can be used as effective researchers to detect the presence of SARS-CoV-2 in many samples in an ELISA test, and can better understand the mechanism of infection of the novel coronavirus.